University of California - Los Angeles Health Sciences May 15 2025 Adoption of lecanemab, a novel infusion treatment for Alzheimer's disease (AD), has been disproportionately higher among patients who are male, white, from urban areas, and have higher socioeconomic status, new research suggests. The findings, published in the peer-reviewed JAMA Network Open , highlight how certain populations are more likely to access potentially breakthrough new therapies than others, the researchers write.